

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

CD133/2 (293C3)-APC, human

RRID:AB_244344

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-090-854, RRID:AB_244344

Antibody Information

URL: http://antibodyregistry.org/AB_244344

Proper Citation: Miltenyi Biotec Cat# 130-090-854, RRID:AB_244344

Target Antigen: CD133/2 (293C3)

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2021; Target Distribution brain, endothelial cells, epithelial cells, heart, hematopoietic stem cells, kidney, liver, lung, pancreas, placenta, ES and iPS cells, red blood cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-184. (RRID:AB_2726010).

Antibody Name: CD133/2 (293C3)-APC, human

Description: This monoclonal targets CD133/2 (293C3)

Target Organism: human

Clone ID: 293C3

Antibody ID: AB_244344

Vendor: Miltenyi Biotec

Catalog Number: 130-090-854

Record Creation Time: 20250820T030120+0000

Record Last Update: 20250820T150821+0000

Ratings and Alerts

No rating or validation information has been found for CD133/2 (293C3)-APC, human.

Warning: Discontinued: 2021

Discontinued: 2021; Target Distribution brain, endothelial cells, epithelial cells, heart, hematopoietic stem cells, kidney, liver, lung, pancreas, placenta, ES and iPS cells, red blood cells; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-184. (RRID:AB_2726010).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Schniewind I, et al. (2022) Cellular plasticity upon proton irradiation determines tumor cell radiosensitivity. Cell reports, 38(8), 110422.

Gil-Ranedo J, et al. (2021) Viral targeting of glioblastoma stem cells with patient-specific genetic and post-translational p53 deregulations. Cell reports, 36(10), 109673.